MODULE 04 / COMPARISON
Sermorelin vs ipamorelin in the research literature: two modules, one secretagogue bus.
A GHRH analogue and a selective growth-hormone-releasing peptide, wired side by side — same goal of releasing growth hormone, different receptors entirely.
The gist
Sermorelin vs ipamorelin is a comparison of two different switches that turn on the same machine. Sermorelin is a GHRH analogue — it presses the pituitary's GHRH receptor, the natural "release growth hormone" button. Ipamorelin is a GHRP (growth-hormone-releasing peptide) — it presses a different button, the ghrelin/GHS receptor, which the body also uses to release growth hormone. Same outcome, two separate doorways. Because they act on different receptors, researchers discuss combining them, but no clinical combination trial of sermorelin exists. Below, the two mechanisms are laid out module by module.
Two receptors, one outcome
Sermorelin is a GHRH analogue acting on the pituitary GHRH receptor (a class B G-protein-coupled receptor), driving cAMP/PKA signaling to stimulate pulsatile GH release while leaving somatostatin and IGF-1 feedback intact [2][4]. Ipamorelin is a selective growth-hormone-releasing peptide (GHRP) acting on the ghrelin/growth-hormone-secretagogue (GHS) receptor — a completely different receptor in the same secretagogue family [16].
The receptor difference is the whole comparison. They converge on growth-hormone release but enter the system through separate doors, which is why their pharmacology, selectivity, and side-effect profiles differ.
Ipamorelin's selectivity profile
Ipamorelin was characterized as the first selective growth-hormone secretagogue — it releases GH without significant effects on ACTH/cortisol or prolactin [16]. That selectivity is its defining property and distinguishes it from earlier, less specific GHRPs. The selective profile is what made it a reference compound for the GHRP class.
Sermorelin, by contrast, is defined not by selectivity within a peptide class but by being the native GHRH fragment — the body's own pituitary signal, reproduced [7]. One compound is a clean synthetic GHRP; the other is the endogenous GHRH sequence.
Sermorelin vs ipamorelin: what is the difference?
Sermorelin is a GHRH analogue acting on the pituitary GHRH receptor; ipamorelin is a selective growth-hormone-releasing peptide (GHRP) acting on the ghrelin/GHS receptor without significant ACTH, cortisol, or prolactin effects [16]. It is a different mechanism in the same secretagogue family — the same destination reached through a different receptor.
Sermorelin vs tesamorelin: how do they differ?
Both are GHRH analogues; tesamorelin is a stabilized, longer-acting analogue that is FDA-approved for HIV-associated lipodystrophy and reduced visceral adipose tissue versus placebo [18], while sermorelin is the native GHRH(1-29) fragment, formerly approved for pediatric GH deficiency and now compounded. Tesamorelin and ipamorelin sit on opposite sides of this comparison: tesamorelin is GHRH-class like sermorelin, ipamorelin is GHRP-class.
Why the two are discussed together
Because a GHRH analogue and a GHRP act on different receptors, research-user discussions often raise pairing them on a mechanistic rationale. The record characterizes ipamorelin as a selective GHRP [16] but reports no clinical combination trial of sermorelin, so any combination is described as a hypothesis from receptor biology, not an established protocol. Treat the pairing as a mechanistic talking point with no controlled sermorelin combination data behind it.